PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study

References

• BhattDLStegPGOhmanEMREACH Registry InvestigatorsInternational prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosisJAMA2006295180916403930
   PubMed Web of Science ®Google Scholar
• BrownLCJohnsonJAMajumdarSREvidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosisCMAJ200417111899215534311
   PubMed Web of Science ®Google Scholar
• BuseJBTanMHPrinceMJThe effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetesDiabetes Obes Metab200461335614746579
   PubMed Web of Science ®Google Scholar
• CharbonnelBDormandyJErdmannEPROactive Study GroupThe prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patientsDiabetes Care20042716475315220241
   PubMed Web of Science ®Google Scholar
• CharbonnelBScheenAPioglitazone in triple oral therapy: long-term glycaemic results from PROactive [abstract]Diabetes200655Suppl 1A106
   Google Scholar
• CharbonnelBHMatthewsDRSchernthanerGQUARTET Study GroupA long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trialDiabet Med2005a2239940515787663
   PubMed Web of Science ®Google Scholar
• CharbonnelBSchernthanerGBrunettiPLong-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetesDiabetologia2005b48109310415889234
   PubMed Web of Science ®Google Scholar
• ChiassonJLJosseRGGomisRSTOP-NIDDM Trial Research GroupAcarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trialJAMA20032904869412876091
   PubMed Web of Science ®Google Scholar
• ChoiDKimSKChoiSHPreventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetesDiabetes Care20042726546015505001
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNCARDS investigatorsPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trialLancet20043646859615325833
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med1993329977868366922
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFDangeloAThiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepirideHypertens Res2005a289172416555581
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAA comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndromeDiabetes Res Clin Pract2005b6951315955382
   PubMed Web of Science ®Google Scholar
• DormandyJon behalf of the PROactive Writing CommitteePROactive study [letter]Lancet2006367267
   Google Scholar
• DormandyJACharbonnelBEcklandDJPROactive investigatorsSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet200536612798916214598
   PubMed Web of Science ®Google Scholar
• The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trialLancet2006368109610516997664
   PubMed Web of Science ®Google Scholar
• EmbersonJRWhincupPHLawlorDACoronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and womenHeart200591451515772196
   PubMed Web of Science ®Google Scholar
• ErdmannEDormandyJACharbonnelBon behalf of the PROactive investigatorsThe effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction – Results from PROactive (PROactive 05)J Am Coll Cardiol20074917728017466227
   PubMed Web of Science ®Google Scholar
• ErdmannEDormandyJAKupferSMorbidity after reports of serious heart failure in type 2 diabetes patients with underlying cardiovascular disease: results from PROactive [abstract]Circulation2006114Suppl 11848
   Google Scholar
• European Diabetes Policy Group. 1998–1999A Desktop Guide to Type 2 Diabetes Mellitus Accessed 17 September 2006. URL: http://www.staff.ncl.ac.uk/philip.home/t2dgw97r.doc
   Google Scholar
• GaedePParvingHHPedersenOPROactive studyLancet200636723416399142
   PubMedGoogle Scholar
• GaedePVedelPLarsenNMultifactorial intervention and cardiovascular disease in patients with type 2 diabetesN Engl J Med20033483839312556541
   PubMed Web of Science ®Google Scholar
• GoldbergRBKendallDMDeegMAGLAI Study InvestigatorsA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaDiabetes Care20052815475415983299
   PubMed Web of Science ®Google Scholar
• GoldbergRBMelliesMJSacksFMfor the Care InvestigatorsCardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trialCirculation199898251399843456
   PubMed Web of Science ®Google Scholar
• HaffnerSMLehtoSRönnemaaTMortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med1998339229349673301
   PubMed Web of Science ®Google Scholar
• HanefeldMBrunettiPSchernthanerGHQUARTET Study GroupOne-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetesDiabetes Care200427141714693980
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGfor the HOT Study GroupEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study GroupLancet19983511755629635947
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study InvestigatorsEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudyLancet2000355253910675071
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialLancet200336120051612814710
   PubMed Web of Science ®Google Scholar
• HeineRSchindhelmRDiamantMLong-term pioglitazone treatment improves markers of liver function: results from PROactive [Abstract]Diabetes200655Suppl 1A115
   Google Scholar
• HollenbergNKConsiderations for management of fluid dynamic issues associated with thiazolidinedionesAm J Med2003115Suppl 8A111S5S14678876
   PubMedGoogle Scholar
• HomePDPocockSJBeck-NielsenHRosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocolDiabetologia20054817263516025252
   PubMed Web of Science ®Google Scholar
• HorioTSuzukiMSuzukiKPioglitazone improves left ventricular diastolic function in patients with essential hypertensionAm J Hypertens2005189495716053992
   PubMed Web of Science ®Google Scholar
• IdrisIThomsonGASharmaJCDiabetes mellitus and strokeInt J Clin Pract200660485616409428
   PubMed Web of Science ®Google Scholar
• JuutilainenALehtoSRönnemaaTType 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjectsDiabetes Care2005282901716306552
   PubMed Web of Science ®Google Scholar
• KarterAJAhmedATLiuJPioglitazone initiation and subsequent hospitalization for congestive heart failureDiabet Med2005229869316026362
   PubMed Web of Science ®Google Scholar
• KeechASimesRJBarterPFIELD study investigatorsEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet200536618496116310551
   PubMed Web of Science ®Google Scholar
• KoDTMamdaniMAlterDALipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradoxJAMA200429118647015100205
   PubMed Web of Science ®Google Scholar
• LangenfeldMRForstTHohbergCPioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized studyCirculation200511125253115883215
   PubMed Web of Science ®Google Scholar
• LawrenceJMReidJTaylorGJFavorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetesDiabetes Care20042741614693964
   PubMed Web of Science ®Google Scholar
• The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med19983391349579841303
   PubMed Web of Science ®Google Scholar
• MarxNWohrleJNusserTPioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patientsCirculation20051122792816246947
   PubMed Web of Science ®Google Scholar
• Massi-BenedettiMScheenACharbonnelBPioglitazone delays the need for permanent insulin use: results from PROactive [abstract]Diabetes200655Suppl 1A124
   Google Scholar
• MeinertCLKnatterudGLProutTEA study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality resultsDiabetes197019Suppl7898304926376
   PubMedGoogle Scholar
• MiettinenHLehtoSSalomaaVImpact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study GroupDiabetes Care19982169759538972
   PubMed Web of Science ®Google Scholar
• MiyazakiYMahankaliAMatsudaMEffect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patientsJ Clin Endocrinol Metab20028727849112050251
   PubMed Web of Science ®Google Scholar
• MiyazakiYMahankaliAWajcbergEEffect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patientsJ Clin Endocrinol Metab2004894312915356026
   PubMed Web of Science ®Google Scholar
• MukamalKJNestoRWCohenMCImpact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarctionDiabetes Care2001241422711473080
   PubMed Web of Science ®Google Scholar
• NathanDMClearyPABacklundJYDiabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research GroupIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med200535326435316371630
   PubMed Web of Science ®Google Scholar
• NathanDMLachinJClearyPDiabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research GroupIntensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitusN Engl J Med2003348229430312788993
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106314342112485966
   PubMed Web of Science ®Google Scholar
• NigroJOsmanNDartAMInsulin resistance and atherosclerosisEndocr Rev2006272425916492903
   PubMed Web of Science ®Google Scholar
• NikolaidisLALevineTBPeroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure?Cardiol Rev2004121587015078585
   PubMedGoogle Scholar
• PavoIJermendyGVarkonyiTTEffect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetesJ Clin Endocrinol Metab20038816374512679450
   PubMed Web of Science ®Google Scholar
• PerezAKhanMJohnsonTPioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetesDiab Vasc Dis Res20041445016305056
   PubMedGoogle Scholar
• PfutznerAMarxNLubbenGImprovement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer studyJ Am Coll Cardiol20054519253115963388
   PubMed Web of Science ®Google Scholar
• PyöräläKPedersenTRKjekshusJfor the Scandinavian Simvastatin Survival Study (4S) GroupCholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)Diabetes Care199720614209096989
   PubMed Web of Science ®Google Scholar
• RodenMLaaksoMJohnsDLong-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitusDiabet Med2005221101616026380
   PubMed Web of Science ®Google Scholar
• RoperNABilousRWKellyWFExcess mortality in a population with diabetes and the impact of material deprivation: longitudinal population based studyBMJ200132213899311397742
   PubMed Web of Science ®Google Scholar
• RydénLThráinsdóttirISwedbergKAdjudication of serious heart failure in patients from PROactive [letter]Lancet200736818990
   Google Scholar
• SatohNOgawaYUsuiTAntiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effectDiabetes Care2003262493912941708
   PubMed Web of Science ®Google Scholar
• SchaumbergDAGlynnRJJenkinsAJEffect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trialCirculation200511124465315867184
   PubMed Web of Science ®Google Scholar
• ScheenACharbonnelBReduced insulin requirements and improved glycaemic control with pioglitazone in insulin-treated patients with type 2 diabetes: results from PROactive [abstract]Diabetes200655Suppl 1A134
   Google Scholar
• SchernthanerGMatthewsDRCharbonnelBQuartet Study GroupEfficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trialJ Clin Endocrinol Metab20048960687615579760
   PubMed Web of Science ®Google Scholar
• ShepherdJBlauwGJMurphyMBPROSPER study groupPROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialLancet200236016233012457784
   PubMed Web of Science ®Google Scholar
• ShiomiTTsutsuiHHayashidaniSPioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarctionCirculation200210631263212473562
   PubMed Web of Science ®Google Scholar
• SobelBEFryeRDetreKMBypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) TrialCirculation20031076364212566379
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilAWon behalf of the UK Prospective Diabetes Study GroupAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ20003214051210938048
   PubMed Web of Science ®Google Scholar
• St John SuttonMRendellMDandonaPA comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetesDiabetes Care20022520586412401757
   PubMed Web of Science ®Google Scholar
• TakagiTAkasakaTYamamuroATroglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound studyJ Am Coll Cardiol20003615293511079654
   PubMed Web of Science ®Google Scholar
• TakagiTYamamuroATamitaKPioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning studyAm Heart J2003146E512891212
   PubMed Web of Science ®Google Scholar
• TanMHGlazerNBJohnsDJPioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetesCurr Med Res Opin2004a20723815140339
   PubMed Web of Science ®Google Scholar
• TanMHJohnsDJGonzalez GalvezGGLAD Study GroupEffects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trialClin Ther2004b266809315220012
   PubMed Web of Science ®Google Scholar
• TanMHJohnsDJStrandJGLAC Study GroupSustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetesDiabet Med2004c218596615270789
   PubMed Web of Science ®Google Scholar
• TaskinenMRDiabetic dyslipidaemia: from basic research to clinical practiceDiabetologia2003467334912774165
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet1998352837539742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet1998352854659742977
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ1998317703139732337
   PubMed Web of Science ®Google Scholar
• WilcoxRBousserM-GPiragVPROactive 04: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke – results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular EventsStroke2007388657317290029
   PubMed Web of Science ®Google Scholar
• WilcoxRKupferSEffects of pioglitazone on major adverse cardiovascular events (MACE) and myocardial infarction: results from PROactive [abstract]Diabetes200655Suppl 1A74
   Google Scholar
• WynneAMMocanuMMYellonDMPioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPKJ Cardiovasc Pharmacol2005468172216306807
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHThiazolidinedionesN Engl J Med200435111061815356308
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHThe PROactive study: some answers, many questions [commentary]Lancet20053661241216214581
   PubMed Web of Science ®Google Scholar
• ZuanettiGLatiniRMaggioniAPEffect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI-3 studyCirculation1997964239459416888
   PubMed Web of Science ®Google Scholar